Dupont Capital Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Dupont Capital Management’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-11,435	Closed	-$508K	–	1711
2022 Q2	$508K	Hold	11,435	–	–	0.02%	680
2022 Q1	$566K	Sell	11,435 -4,020	-26%	-$193K	0.02%	702
2021 Q4	$787K	Sell	15,455 -6,162	-29%	-$319K	0.03%	627
2021 Q3	$1.21M	Sell	21,617 -3,056	-12%	-$150K	0.04%	481
2021 Q2	$1.06M	Buy	+24,673	New	+$1.02M	0.02%	555
2019 Q2	–	Sell	-18,131	Closed	-$915K	–	1280
2019 Q1	$915K	Hold	18,131	–	–	0.02%	575
2018 Q4	$730K	Buy	18,131 +12,695	+234%	+$654K	0.02%	621
2018 Q3	$377K	Hold	5,436	–	–	0.01%	772
2018 Q2	$411K	Hold	5,436	–	–	0.01%	748
2018 Q1	$286K	Sell	5,436 -9,699	-64%	-$564K	0.01%	772
2017 Q4	$809K	Buy	+15,135	New	+$842K	0.02%	562
2017 Q3	–	Sell	-8,465	Closed	-$668K	–	999
2017 Q2	$668K	Buy	8,465 +4,380	+107%	+$358K	0.01%	613
2017 Q1	$339K	Hold	4,085	–	–	0.01%	770
2016 Q4	$324K	Buy	+4,085	New	+$297K	0.01%	762

Other funds holding EGRX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

DZ Bank Frankfurt Am Main, Germany $113B AUM 36.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Dupont Capital Management's EGRX Position: Q3 2022 in Review

Dupont Capital Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2022, closing a stake of 11,435 shares — an estimated $508K sold.

Dupont Capital Management first reported a position in EGRX in Q4 2016 and held it in 14 quarters. The position peaked at $1.21M in Q3 2021. 153 funds tracked by Wall St. Rank hold EGRX as of Q3 2022.

Dupont Capital Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2022 after selling out during the quarter.
Dupont Capital Management sold 11,435 Eagle Pharmaceuticals, Inc. shares in Q3 2022, an estimated $508K.
Dupont Capital Management first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2016 and held it in 14 quarters.
Dupont Capital Management's Eagle Pharmaceuticals, Inc. position peaked at $1.21M in Q3 2021.
153 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2022.

Based on Dupont Capital Management's 13F filing for Q3 2022, filed 31 Oct 2022.